– The denim retailer gained more than 1% after Guggenheim raised its price target on the company to $24, up from a prior target of $20. The new forecast is 21% above where the stock closed on Tuesday. "We are encouraged by the company's offensive strategy, strong brand, experienced management team, and healthy financial position … which we believe will allow LEVI to emerge from COVID-19 disruption in a stronger competitive position," the firm said in a note to clients.
initiated coverage on the software company with a buy rating. said it sees growth in the application performance management market in 2021 as more companies invest in digital transformation. The firm's $56 price target suggests a 30% rally in the next 12 months.
If it weren't for the good folks of Astra zeneca I would not To be able to get my diabetic medicine. Really great company with a lot of good people that work for them.